PHASE I SAFETY AND FEASIBILITY STUDY OF A PERSONAL NEOANTIGEN-TARGETING VACCINE IN COMBINATION WITH IMMUNE CHECKPOINT BLOCKADE IN OVARIAN CANCER
$1,059,000FY2018Department of the ArmyDOD
Dana-Farber Cancer Institute, Inc.
Dana-Farber Cancer Institute, Inc.